Literature DB >> 27509070

Defining Glioblastoma Resectability Through the Wisdom of the Crowd: A Proof-of-Principle Study.

Adam M Sonabend1, Brad E Zacharia2, Michael B Cloney1, Aarón Sonabend3, Christopher Showers1, Victoria Ebiana1, Matthew Nazarian1, Kristin R Swanson4, Anne Baldock5, Henry Brem6, Jeffrey N Bruce1, William Butler7, Daniel P Cahill7, Bob Carter8, Daniel A Orringer9, David W Roberts10, Oren Sagher9, Nader Sanai11, Theodore H Schwartz12, Daniel L Silbergeld13, Michael B Sisti1, Reid C Thompson14, Allen E Waziri15, Zoher Ghogawala16, Guy McKhann1.   

Abstract

BACKGROUND: Extent of resection (EOR) correlates with glioblastoma outcomes. Resectability and EOR depend on anatomical, clinical, and surgeon factors. Resectability likely influences outcome in and of itself, but an accurate measurement of resectability remains elusive. An understanding of resectability and the factors that influence it may provide a means to control a confounder in clinical trials and provide reference for decision making.
OBJECTIVE: To provide proof of concept of the use of the collective wisdom of experienced brain tumor surgeons in assessing glioblastoma resectability.
METHODS: We surveyed 13 academic tumor neurosurgeons nationwide to assess the resectability of newly diagnosed glioblastoma. Participants reviewed 20 cases, including digital imaging and communications in medicine-formatted pre- and postoperative magnetic resonance images and clinical vignettes. The selected cases involved a variety of anatomical locations and a range of EOR. Participants were asked about surgical goal, eg, gross total resection, subtotal resection (STR), or biopsy, and rationale for their decision. We calculated a "resectability index" for each lesion by pooling responses from all 13 surgeons.
RESULTS: Neurosurgeons' individual surgical goals varied significantly ( P = .015), but the resectability index calculated from the surgeons' pooled responses was strongly correlated with the percentage of contrast-enhancing residual tumor ( R = 0.817, P < .001). The collective STR goal predicted intraoperative decision of intentional STR documented on operative notes ( P < .01) and nonresectable residual ( P < .01), but not resectable residual.
CONCLUSION: In this pilot study, we demonstrate the feasibility of measuring the resectability of glioblastoma through crowdsourcing. This tool could be used to quantify resectability, a potential confounder in neuro-oncology clinical trials.
Copyright © 2016 by the Congress of Neurological Surgeons

Entities:  

Keywords:  Crowdsourcing; EOR; Extent of resection; Glioblastoma; Glioma; Resectability

Mesh:

Year:  2017        PMID: 27509070      PMCID: PMC5888974          DOI: 10.1227/NEU.0000000000001374

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  47 in total

1.  A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.

Authors:  Manfred Westphal; Dana C Hilt; Enoch Bortey; Patrick Delavault; Robert Olivares; Peter C Warnke; Ian R Whittle; Juha Jääskeläinen; Zvi Ram
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

2.  The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere.

Authors:  G E Keles; B Anderson; M S Berger
Journal:  Surg Neurol       Date:  1999-10

3.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival.

Authors:  M Lacroix; D Abi-Said; D R Fourney; Z L Gokaslan; W Shi; F DeMonte; F F Lang; I E McCutcheon; S J Hassenbusch; E Holland; K Hess; C Michael; D Miller; R Sawaya
Journal:  J Neurosurg       Date:  2001-08       Impact factor: 5.115

4.  Glioblastoma multiforme-report of 267 cases treated at a single institution.

Authors:  Andreas M Stark; Arya Nabavi; Hubertus Maximilian Mehdorn; Ulrike Blömer
Journal:  Surg Neurol       Date:  2005-02

5.  Effect of surgical removal on survival and quality of life in patients with supratentorial glioblastoma.

Authors:  Yukitaka Ushio; Masato Kochi; Jun-ichiro Hamada; Yutaka Kai; Hideo Nakamura
Journal:  Neurol Med Chir (Tokyo)       Date:  2005-09       Impact factor: 1.742

6.  Ventral versus dorsal decompression for cervical spondylotic myelopathy: surgeons' assessment of eligibility for randomization in a proposed randomized controlled trial: results of a survey of the Cervical Spine Research Society.

Authors:  Zoher Ghogawala; Jean-Valery Coumans; Edward C Benzel; Lauren M Stabile; Fred G Barker
Journal:  Spine (Phila Pa 1976)       Date:  2007-02-15       Impact factor: 3.468

7.  Cortical and subcortical motor mapping in rolandic and perirolandic glioma surgery: impact on postoperative morbidity and extent of resection.

Authors:  G Carrabba; E Fava; C Giussani; F Acerbi; F Portaluri; V Songa; N Stocchetti; V Branca; S M Gaini; L Bello
Journal:  J Neurosurg Sci       Date:  2007-06       Impact factor: 2.279

8.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

9.  Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis.

Authors:  Kathleen R Lamborn; Susan M Chang; Michael D Prados
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

10.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

Authors:  James J Vredenburgh; Annick Desjardins; James E Herndon; Jennifer Marcello; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Melissa Wagner; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman
Journal:  J Clin Oncol       Date:  2007-10-20       Impact factor: 44.544

View more
  12 in total

1.  Is a pretreatment radiological staging system feasible for suggesting the optimal extent of resection and predicting prognosis in glioblastoma? An observational study.

Authors:  Jaume Capellades; Josep Puig; Sira Domenech; Teresa Pujol; Laura Oleaga; Angels Camins; Carles Majós; Rocio Diaz; Christian de Quintana; Pilar Teixidor; Gerard Conesa; Gerard Plans; Josep Gonzalez; Natalia García-Balañà; Jose Maria Velarde; Carmen Balaña
Journal:  J Neurooncol       Date:  2017-12-28       Impact factor: 4.130

2.  Craniotomy and Survival for Primary Central Nervous System Lymphoma.

Authors:  Ali I Rae; Amol Mehta; Michael Cloney; Connor J Kinslow; Tony J C Wang; Govind Bhagat; Peter D Canoll; George J Zanazzi; Michael B Sisti; Sameer A Sheth; E Sander Connolly; Guy M McKhann; Jeffrey N Bruce; Fabio M Iwamoto; Adam M Sonabend
Journal:  Neurosurgery       Date:  2019-04-01       Impact factor: 4.654

3.  The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis.

Authors:  Michael Brendan Cloney; Adam M Sonabend; Jonathan Yun; Jingyan Yang; Fabio Iwamoto; Suprit Singh; Govind Bhagat; Peter Canoll; George Zanazzi; Jeffrey N Bruce; Michael Sisti; Sameer Sheth; E Sander Connolly; Guy McKhann
Journal:  J Neurooncol       Date:  2017-01-23       Impact factor: 4.130

4.  A consensus definition of supratotal resection for anatomically distinct primary glioblastoma: an AANS/CNS Section on Tumors survey of neurosurgical oncologists.

Authors:  Maureen Rakovec; Adham M Khalafallah; Oren Wei; David Day; Jason P Sheehan; Jonathan H Sherman; Debraj Mukherjee
Journal:  J Neurooncol       Date:  2022-08-01       Impact factor: 4.506

Review 5.  Newly Diagnosed Glioblastoma: A Review on Clinical Management.

Authors:  Rimas V Lukas; Derek A Wainwright; Erik Ladomersky; Sean Sachdev; Adam M Sonabend; Roger Stupp
Journal:  Oncology (Williston Park)       Date:  2019-03-13       Impact factor: 2.990

Review 6.  MalaCards: an amalgamated human disease compendium with diverse clinical and genetic annotation and structured search.

Authors:  Noa Rappaport; Michal Twik; Inbar Plaschkes; Ron Nudel; Tsippi Iny Stein; Jacob Levitt; Moran Gershoni; C Paul Morrey; Marilyn Safran; Doron Lancet
Journal:  Nucleic Acids Res       Date:  2016-11-28       Impact factor: 16.971

7.  Assessing the Safety of Craniotomy for Resection of Primary Central Nervous System Lymphoma: A Nationwide Inpatient Sample Analysis.

Authors:  Jonathan Yun; Jingyan Yang; Michael Cloney; Amol Mehta; Suprit Singh; Fabio Massaiti Iwamoto; Alfred I Neugut; Adam M Sonabend
Journal:  Front Neurol       Date:  2017-09-12       Impact factor: 4.003

8.  Comparing Glioblastoma Surgery Decisions Between Teams Using Brain Maps of Tumor Locations, Biopsies, and Resections.

Authors:  Domenique M J Müller; Pierre A J T Robe; Roelant S Eijgelaar; Marnix G Witte; Martin Visser; Jan C de Munck; Marieke L D Broekman; Tatjana Seute; Jeroen Hendrikse; David P Noske; William P Vandertop; Frederik Barkhof; Mathilde C M Kouwenhoven; Emmanuel Mandonnet; Mitchel S Berger; Philip C De Witt Hamer
Journal:  JCO Clin Cancer Inform       Date:  2019-01

9.  A Crowdsourced Consensus on Supratotal Resection Versus Gross Total Resection for Anatomically Distinct Primary Glioblastoma.

Authors:  Adham M Khalafallah; Maureen Rakovec; Chetan Bettegowda; Christopher M Jackson; Gary L Gallia; Jon D Weingart; Michael Lim; Yoshua Esquenazi; Brad E Zacharia; Ezequiel Goldschmidt; Mateo Ziu; Michael E Ivan; Andrew S Venteicher; Edjah K Nduom; Adam N Mamelak; Ray M Chu; John S Yu; Jason P Sheehan; Brian V Nahed; Bob S Carter; Mitchel S Berger; Raymond Sawaya; Debraj Mukherjee
Journal:  Neurosurgery       Date:  2021-09-15       Impact factor: 5.315

10.  Collaboration between a human group and artificial intelligence can improve prediction of multiple sclerosis course: a proof-of-principle study.

Authors:  Andrea Tacchella; Silvia Romano; Michela Ferraldeschi; Marco Salvetti; Andrea Zaccaria; Andrea Crisanti; Francesca Grassi
Journal:  F1000Res       Date:  2017-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.